We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

78 hedge funds and large institutions have $113M invested in Viracta Therapeutics, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $1.81M | Put options by funds: $903K

16% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 25

25% less funds holding

Funds holding: 104 → 78 (-26)

52% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 44

70% less capital invested

Capital invested by funds: $380M → $113M (-$268M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
78
Holders Change
-26
Holders Change %
-25%
% of All Funds
2.08%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
21
Increased
21
Reduced
25
Closed
44
Calls
$1.81M
Puts
$903K
Net Calls
+$904K
Net Calls Change
-$9.3M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$6.87M
2
BI
BVF Inc
California
+$6.73M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$4.76M
4
First Eagle Investment Management
First Eagle Investment Management
New York
+$3.03M
5
Morgan Stanley
Morgan Stanley
New York
+$2.1M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$34.8M
2
EAM
Eagle Asset Management
Florida
-$16.7M
3
LCP
Lamond Capital Partners
California
-$9.43M
4
Franklin Resources
Franklin Resources
California
-$9.38M
5
O
OrbiMed
New York
-$8.57M
Name Holding Trade Value Shares
Change 		Change in
Stake
DA
26
DSC Advisors
Illinois
$574K +$107K +238 +29%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$542K -$271K -602 -37%
Federated Hermes
28
Federated Hermes
Pennsylvania
$510K -$66.7K -148 -13%
HVC
29
Healthcare Value Capital
New Jersey
$510K +$375K +833 +700%
AGCJ
30
Alden Global Capital (Jersey)
Jersey
$480K +$404K +896 New
TCIM
31
TIAA CREF Investment Management
New York
$446K -$10.8K -24 -3%
BIM
32
BlackRock Investment Management
Delaware
$370K +$901 +2 +0.3%
TD Asset Management
33
TD Asset Management
Ontario, Canada
$341K – – –
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$322K +$271K +601 New
CS
35
Credit Suisse
Switzerland
$317K +$210K +467 +374%
Goldman Sachs
36
Goldman Sachs
New York
$316K +$50.9K +113 +24%
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$276K -$30.2K -67 -11%
NFA
38
Nationwide Fund Advisors
Ohio
$263K +$16.2K +36 +8%
AIG
39
American International Group
New York
$244K -$28.8K -64 -12%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$234K +$901 +2 +0.5%
Bank of America
41
Bank of America
North Carolina
$205K +$161K +357 +1,373%
Charles Schwab
42
Charles Schwab
California
$186K -$84.7K -188 -35%
TA
43
Teachers Advisors
New York
$175K – – –
HCM
44
Highbridge Capital Management
New York
$154K +$129K +287 New
PPA
45
Parametric Portfolio Associates
Washington
$135K -$19.4K -43 -15%
WMSA
46
Weiss Multi-Strategy Advisers
New York
$128K +$107K +238 New
Jacobs Levy Equity Management
47
Jacobs Levy Equity Management
New Jersey
$107K +$89.7K +199 New
Group One Trading
48
Group One Trading
Illinois
$106K +$89.2K +198 New
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$105K +$4.96K +11 +6%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$98K – – –
1
2
3 4 5

VIRX Hedge Fund Activity: Q4 2014 in Review

78 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2014, worth a combined $113M — down 70% from $380M a quarter earlier.

Sellers outnumbered buyers: 44 funds closed out of VIRX and 21 opened new positions — a net loss of 23 holders — while 25 trimmed existing stakes and 21 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $6.87M. The largest seller was RA Capital Management, exiting entirely with an estimated $34.8M sold.

  • 78 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2014, down from 104 in Q3 2014.
  • Funds reported $113M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2014, down 70% quarter-over-quarter.
  • 21 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2014 and 44 closed out, a net change of -23 holders.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2014 was Baker Bros. Advisors, an estimated $6.87M added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2014 was RA Capital Management, an estimated $34.8M sold.

Based on aggregated 13F filings for Q4 2014.